MARKET

ZIOP

ZIOP

ZIOPHARM Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.640
-0.340
-6.83%
After Hours: 4.600 -0.04 -0.86% 16:12 01/17 EST
OPEN
5.00
PREV CLOSE
4.980
HIGH
5.03
LOW
4.615
VOLUME
2.07M
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.920
MARKET CAP
839.98M
P/E (TTM)
6.89
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ZIOP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ZIOP News

  • ZIOPHARM Oncology Option Alert: Jul 17 $6 Calls Sweep (2) near the Ask: 20000 @ $1.2 vs 57 OI; Earnings 3/3 After Close [est] Ref=$4.68
  • Benzinga.5d ago
  • ZIOPHARM Oncology Option Alert: Jul 17 $5 Calls Sweep (2) near the Ask: 500 @ $1.0 vs 176 OI; Ref=$4.47
  • Benzinga.01/02 16:25
  • ZIOPHARM Oncology Option Alert: Jan 17 $5.5 Calls Sweep (28) near the Ask: 1041 @ $0.201 vs 4036 OI; Ref=$4.9
  • Benzinga.12/30/2019 16:40
  • Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
  • Zacks.12/30/2019 13:56

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
More

Webull offers ZIOPHARM Oncology Inc. (ZIOP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.